Proxi Biotech
Proxi Biotech, an early stage spin-off from Staten Serum Institute, has developed the BID Technology for detoxification of bacterial toxins to be used as next generation vaccine antigens. BID Technology replaces the conventional cross-reacting agents in the development of new antigens for toxoid-based vaccines that are highly needed to overcome the challenges of antimicrobial resistance.
| Location | Denmark |
| Website | proxibiotech.com |
| Founded | 2018 |
| Employees | 1-10 |
| Industries | Healthcare & Life Science |
| Business model | - |
| Funding state | - |
Working at
Proxi Biotech
This job comes with several perks and benefits
Flexible working hours
Time is precious. Make it count. Morning person or night owl, this job is for you.
Social gatherings
Social gatherings and games; hang out with your colleagues.
Near public transit
Easy access and treehugger friendly workplace.
Free coffee / tea
Get your caffeine fix to get you started and keep you going.
Pension plan
We take care of you, even when you are old and wrinkly.
Team
KØ
CEO